News Quantified

ANIP – ani pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $86.00 price target on the stock.

IBD 50 Stock Flashes 'Golden Cross' But Massive Risk Looms [Yahoo! Finance]

Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? [Yahoo! Finance]

Peptide Antibiotics Industry Report 2025 | Antibiotic Resistance Crisis Fuels Demand as Market Surges Toward USD 8.4 Billion [Yahoo! Finance]

ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET

11.4%

BEAT

4.0%

BEAT

-0.1%

BEAT

4.9%

BEAT

Form ARS ANI PHARMACEUTICALS INC For: Dec 31

Form DEFA14A ANI PHARMACEUTICALS INC

Form DEF 14A ANI PHARMACEUTICALS INC For: Dec 31

Form SCHEDULE 13G/A ANI PHARMACEUTICALS INC Filed by: MILLENNIUM MANAGEMENT LLC

Form PRE 14A ANI PHARMACEUTICALS INC For: Dec 31

Top News Gainers

3/24 ANI Pharmaceuticals Announces the Filing of a Prior Approval Supplement for Purified Cortrophin® Gel 80 U/mL 18.7%

6/18 ANI Pharmaceuticals Expands Generic Pipeline with Acquisition of Seven Development Stage Drug Products from Coeptis Pharmaceuticals, Inc. 10.0%

4/8 Form 4 ANI PHARMACEUTICALS INC For: Apr 06 Filed by: Schrepfer Robert W 8.0%

4/13 ANI Announces FDA Acceptance of Supplemental Filing for Cortrophin® Gel 80 U/mL 6.1%

9/12 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 5.6%

9/12 ANI Pharmaceuticals Inc (NASDAQ: ANIP) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. 4.1%

1/9 ANI Pharmaceuticals Announces Acquisition of Commercial and Pipeline Generic Products from Amerigen Pharmaceuticals, Ltd. 3.5%

6/28 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.4%

5/9 Q1/2019 3/31/2019 EPS 1.300 ZacksConsensus 1.030 ActVsEst 0.270 - Beat 3.1%

10/22 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.0%

Top News Decliners

11/6 Q3/2019 9/30/2019 EPS 1.230 ZacksConsensus 1.320 ActVsEst (0.090) - Miss -23.7%

2/27 Q4/2019 12/31/2019 EPS 1.080 ZacksConsensus 1.020 ActVsEst 0.060 - Beat -18.7%

8/7 Q2/2019 6/30/2019 EPS 1.440 ZacksConsensus 1.180 ActVsEst 0.260 - Beat -15.1%

4/14 ANI Announces Upcoming Departure of CEO -9.0%

3/2 ANI Pharmaceuticals Announces FDA Approval of Memantine Hydrochloride Extended-Release Capsules -7.8%

3/4 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.3%

3/7 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.4%

3/31 Form 4 ANI PHARMACEUTICALS INC For: Mar 28 Filed by: PRZYBYL ARTHUR -6.3%

4/14 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -6.0%

1/7 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -5.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day